|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
FEBRUARY 6, 2006
If Clinical Trials Pan Out, GTx Could Have A Winner  Tiny Biotech GTx (GTXI
) develops drugs mainly for prostate cancer. GTx' lead product, Acapodene, is in Phase 3 clinical trials for prevention of prostate cancer in men with precancerous lesions. Acapodene inhibits estrogen's harmful effects on patients treated for prostate problems -- after their testosterone production is interrupted. "We expect the trials will be successful," says Mark Basham of Standard & Poor's (MHP
). He rates the stock, now at 9, a four-star buy (five stars is tops), with a 12-month target of 18. It's a high-risk stock, he warns, since it depends on the trials' outcome. But if Acapodene succeeds, the market for it could be $3 billion a year, Basham says. Acapodene's other use is to shrink tumors in men already suffering from prostate cancer. Another GTx drug, Andarine, counters weight loss in cancer patients. Its Phase 1 tests for safety are completed. Andarine is being developed together with Johnson & Johnson's (JNJ
) Ortho Biotech unit. CEO Mitchell Steiner is seeking a partner for Acapodene. J&J, he says, is a possibility for Europe and Asia, but GTx is also in talks with others. GTx, whose top officers control 60% of the stock, will handle the U.S. market. Steiner will seek approval for Acapodene in late 2007 and possibly market it in 2008.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2006, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version